Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcadia Biosciences, Inc.RKDA · Entity 8593 | Chief Technology Officer | January 21, 2021 | January 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcadia Biosciences, Inc.
Report date January 21, 2021 · Filed January 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,000 |
Reported balance
After 2020-08-03 transaction · row 1
1 source rowRow 1 · 2020-08-03 · Purchase · Acquired 700 · Balance 13,000 F1: Reflects the purchase of 700 shares of the Issuer's Common Stock on 8/3/20 at a per share purchase price of $3.16 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.05 · Expires 2031-01-21 | Direct | 115,000 |
Reported balance
After 2021-01-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-21 · Grant · Acquired 55,000 · Balance 115,000 F2: The options will vest monthly in equal installments over a period of four years from the date of the grant, 01/21/2021, subject to the Participant's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the purchase of 700 shares of the Issuer's Common Stock on 8/3/20 at a per share purchase price of $3.16 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan.
F2: The options will vest monthly in equal installments over a period of four years from the date of the grant, 01/21/2021, subject to the Participant's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2021 Filed Jan 25, 2021 18:47 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-005218 · doc4.xml · derivative · entry 2 Shultz Randall · CIK 0001808500 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 55,000 shares Expires 2031-01-21 F2 · derivative.exercise_date: The options will vest monthly in equal installments over a period of four years from the date of the grant, 01/21/2021, subject to the Participant's continued service. Read SEC document |
| August 03, 2020 Filed Jan 25, 2021 18:47 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | PurchaseCommon Stock | 700 | $3.16 | $2,212.00 |
DisclosureSEC source: 0001209191-21-005218 · doc4.xml · nonDerivative · entry 1 Shultz Randall · CIK 0001808500 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · shares: Reflects the purchase of 700 shares of the Issuer's Common Stock on 8/3/20 at a per share purchase price of $3.16 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 17:31 UTC | Arcadia Biosciences, Inc. RKDA · Entity 8593 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-20-023345 · doc4.xml · derivative · entry 1 Shultz Randall · CIK 0001808500 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 18,000 shares Expires 2030-04-01 F1 · derivative.exercise_date: The option vests in 48 equal installments beginning April 30, 2020 and ending March 31, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.